Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Active, not recruiting · Phase 1 · NCT06667687
Conditions: Non-Hodgkin's Lymphoma
At a glance
- Research payments reported, 2025
- $322,557
- U.S. investigators named
- 7
- Sites paid
- 8
- Planned or actual enrollment
- 21
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-291 (drug)
- Dates
- Started 2025-01-16; completion 2031-11
- Results posted
- Not yet
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed. ABBV-291 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-291 and a dose expa…
From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $322,557 in research payments for this study in 2025 (90 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexander Philipovskiy, M.D., PH.D Medical Oncology · Sanford, FL
- Neel J. Gandhi, M.D. Hematology & Oncology · Lawrenceville, NJ
- Jeff P. Sharman, M.D. Medical Oncology · Eugene, OR
- Krish Patel, M.D. Hematology & Oncology · Nashville, TN
- Jason M. Melear, M.D. Medical Oncology · Austin, TX
- Justin A. Call, M.D. Medical Oncology · West Jordan, UT
- Mohamad A. Salkeni, M.D. Hematology & Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute LLC $160,560
- Start Mountain Region LLC $82,857
- Next Virginia LLC $39,517
- Carolina Biooncology Institute PLLC $34,233
- $2,448
- US Oncology Research LLC $1,296
- Sarah Cannon Research Institute $696
- Carolina Biooncology Institute $500
- Start Mountain Region $450
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.